AHN and MQ contributed equally. All authors have lived experience of diabetes as well as professional or voluntary experience in health-care provision, research studies, and advocacy. The views in this Comment are those of the individual authors and not the organisations for which they work or volunteer. This Comment was prepared without external involvement or funding. AHN is supported by funding from the Medical Research Future Fund (paid to her institution); has received funding from the University of Technology Sydney and the Australian Diabetes Educators Association, consulting payments from Aarian Health, and honoraria from Dietitians Australia; and is a board member of the Primary Care Diabetes Society of Australia, chair of the Diabetes Australia Kellion Advisory Committee, a member of the Diabetes Victoria Community Advisory Committee, an advisory committee member for Patient Voice Initiative, a community advisory member of the Australasian Type 1 Diabetes Immunotherapy Collaborative, and has previously worked with Safer Care Victoria as a consumer representative on several short-term projects. MQ is employed by the Australian Living Evidence Collaboration, Monash University School of Public Health and Preventive Medicine, and has received travel and accommodation support from the Rio Tinto Children's Diabetes Centre. RH is supported by an Educational Research Grant for a PhD project from Australasian Diabetes In Pregnancy Society (ADIPS) and Novo Nordisk (paid to Western Sydney University), a School of Medicine PhD stipend from Western Sydney University (paid to self) and a PhD top-up scholarship from JDRF (paid to self); and received travel grants from JDRF, the Western Sydney University School of Medicine, and the ADIPS/International Association for Diabetes and Pregnancy Study Group. BN is supported by a PhD stipend through the Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, the Rowden White PhD top-up scholarship 2023, the Australian Centre for Accelerating Diabetes Innovations (ACADI) PhD top-up scholarship 2024, and the Diabetes Victoria Gwen Scott grant 2023; and reports speaking fees from Insulet and travel support from Insulet and JDRF. MR is a member of the Australian Centre for Accelerating Diabetes Innovations Community Engagement Panel and Co-design platform and is chair of the Australasian Type 1 Diabetes Immunotherapy Collaborative Engagement Panel. RS has received consulting and honorarium payments from Lilly Diabetes, Novo Nordisk, Ascensia Diabetes Care, Insulet, Ypsomed, and Medtronic; is employed by JDRF International and #dedoc°; is chair of the ACADI community advisory board; and has previously worked with Diabetes Australia. LT has received travel support from #dedoc° and Diabetes Australia; has participated on the Diabetes Australia Community Advisory Council 2023–24 and the Australasian Type 1 Diabetes Immunotherapy Collaborative Community Engagement Panel 2023–24; and is the leader of the Blue Circle Cycling Club, a social group promoting exercise for people with type 1 diabetes. EHT is supported by the core funding to the Australian Centre for Behavioural Research in Diabetes provided by the collaboration between Diabetes Victoria and Deakin University; has received funding from the Diabetes Australia Research Program, the Medical Research Future Fund Targeted Translational Research Accelerator Project, and the National Health and Medical Research Council of Australia; and has received an investigator-initiated grant from Sanofi Diabetes (paid to her research institution), an unrestricted educational grant from Diabetes Australia, and sponsorship to attend and present at educational meetings from Roche Diabetes Care. All other authors declare no competing interests.